David J Adelstein

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. doi request reprint Biology and management of salivary gland cancers
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Semin Radiat Oncol 22:245-53. 2012
  2. doi request reprint Clinical trial design in head and neck cancer: what has the oncologist learned?
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Lancet Oncol 13:e318-23. 2012
  3. ncbi request reprint Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia
    David J Adelstein
    Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    Head Neck 34:1681-703. 2012
  4. doi request reprint A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction
    David J Adelstein
    Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Invest New Drugs 30:1684-9. 2012
  5. doi request reprint Current and emerging standards of concomitant chemoradiotherapy
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Semin Oncol 35:211-20. 2008
  6. doi request reprint What is new in the management of salivary gland cancers?
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Curr Opin Oncol 23:249-53. 2011
  7. ncbi request reprint Concurrent chemoradiotherapy in the management of squamous cell cancer of the oropharynx: current standards and future directions
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 69:S37-9. 2007
  8. ncbi request reprint Oropharyngeal cancer: the role of chemotherapy
    David J Adelstein
    The Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Treat Options Oncol 4:3-13. 2003
  9. doi request reprint Human papillomavirus: changing paradigms in oropharyngeal cancer
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Desk R 35, 9500 Euclid Avenue, Cleveland, OH, 44195, USA
    Curr Oncol Rep 12:115-20. 2010
  10. ncbi request reprint Systemic chemotherapy for squamous cell head and neck cancer
    David J Adelstein
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Desk R 35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Expert Opin Pharmacother 4:2151-63. 2003

Detail Information

Publications61

  1. doi request reprint Biology and management of salivary gland cancers
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Semin Radiat Oncol 22:245-53. 2012
    ..These efforts have suggested the potential for molecularly targeted therapies, and clinical trials exploring this approach are currently underway...
  2. doi request reprint Clinical trial design in head and neck cancer: what has the oncologist learned?
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Lancet Oncol 13:e318-23. 2012
    ....
  3. ncbi request reprint Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia
    David J Adelstein
    Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    Head Neck 34:1681-703. 2012
    ..The proceedings of this meeting are summarized...
  4. doi request reprint A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction
    David J Adelstein
    Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Invest New Drugs 30:1684-9. 2012
    ..We report results from a phase II trial in this population using gefitinib, an oral epidermal growth factor receptor inhibitor...
  5. doi request reprint Current and emerging standards of concomitant chemoradiotherapy
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Semin Oncol 35:211-20. 2008
    ....
  6. doi request reprint What is new in the management of salivary gland cancers?
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Curr Opin Oncol 23:249-53. 2011
    ..Historically they have been treated with surgery and radiation therapy. It is only recently that there has been any growth in our understanding of these diseases and their management, and this progress will be reviewed...
  7. ncbi request reprint Concurrent chemoradiotherapy in the management of squamous cell cancer of the oropharynx: current standards and future directions
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 69:S37-9. 2007
  8. ncbi request reprint Oropharyngeal cancer: the role of chemotherapy
    David J Adelstein
    The Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Treat Options Oncol 4:3-13. 2003
    ..Continued enrollment of patients in well-designed and conducted clinical trials is of paramount importance...
  9. doi request reprint Human papillomavirus: changing paradigms in oropharyngeal cancer
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Desk R 35, 9500 Euclid Avenue, Cleveland, OH, 44195, USA
    Curr Oncol Rep 12:115-20. 2010
    ..The potential for disease prevention with the use of the current HPV vaccines is discussed...
  10. ncbi request reprint Systemic chemotherapy for squamous cell head and neck cancer
    David J Adelstein
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Desk R 35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Expert Opin Pharmacother 4:2151-63. 2003
    ..In this article, the available data supporting the use of systemic chemotherapy as palliative treatment, and as part of the definitive management for this disease will be reviewed...
  11. ncbi request reprint A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity
    David J Adelstein
    The Taussig Cancer Center and the Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Am J Clin Oncol 30:172-80. 2007
    ..A split course of pre- and postoperative hyperfractionated radiation therapy and concurrent chemotherapy was used in an effort to limit perioperative mortality...
  12. ncbi request reprint Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?
    David J Adelstein
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 24:2624-8. 2006
    ..This treatment approach remains investigational however, and these phase III studies are critical. The current randomized trials are reviewed and discussed...
  13. ncbi request reprint An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer
    David J Adelstein
    Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Ohio 44195, USA
    J Clin Oncol 21:92-8. 2003
    ..The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer...
  14. ncbi request reprint Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution
    David J Adelstein
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 24:1064-71. 2006
    ..A retrospective review with long-term follow-up is reported from the Cleveland Clinic Foundation studying radiation and concurrent multiagent chemotherapy in patients with locoregionally advanced squamous cell head and neck cancer...
  15. ncbi request reprint Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy
    D J Adelstein
    Departments of Hematology and Medical Oncology, Thoracic and Cardiovascular Surgery, Biostatistics and Epidemiology, Radiation Oncology, and Gastroenterology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 18:2032-9. 2000
    ....
  16. ncbi request reprint The role of chemotherapy for skull base carcinomas and sarcomas
    D J Adelstein
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Neurosurg Clin N Am 11:681-91. 2000
    ..The ultimate role of this intervention in the aggressive sinonasal undifferentiated carcinomas and primary neuroendocrine carcinomas is unknown, but for these diseases, chemotherapy is a reasonable addition to locoregional treatment...
  17. doi request reprint Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    J Thorac Oncol 4:1264-9. 2009
    ..Mature results are presented from a phase II trial of postoperative concurrent chemoradiotherapy in patients with poor-prognosis cancer of the esophagus and gastroesophageal junction after primary surgical resection...
  18. pmc Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria
    David J Adelstein
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    Head Neck 32:221-8. 2010
    ....
  19. ncbi request reprint Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy
    David J Adelstein
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 20:1405-10. 2002
    ..Results are reported from an aggressive chemoradiotherapy protocol for advanced squamous cell head and neck cancer...
  20. ncbi request reprint Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer
    David J Adelstein
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, OH 44195, USA
    Lung Cancer 36:167-74. 2002
    ..Patients downstaged to mediastinal node negativity have a prognosis similar to those with de novo stage I(B) and II disease. Distant metastases are the major cause of treatment failure...
  21. doi request reprint A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer
    Cristina P Rodriguez
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    J Thorac Oncol 5:229-35. 2010
    ..This phase II study added gefitinib (G) to our previously tested CCRT regimen in an effort to improve these outcomes...
  22. doi request reprint Induction chemoradiotherapy increases pleural and pericardial complications after esophagectomy for cancer
    Sudish C Murthy
    Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH 44195, USA
    J Thorac Oncol 4:395-403. 2009
    ..This study focuses on postesophagectomy benign pleural and pericardial complications to determine their prevalence, temporal pattern, and treatment, and their association with induction chemoradiotherapy and influence on survival...
  23. doi request reprint Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy
    Cristina P Rodriguez
    Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio, USA
    Head Neck 30:1535-42. 2008
    ..Determining which patients benefit from larynx preservation strategies remains problematic. We reviewed our experience using multiagent concurrent chemoradiotherapy to identify clinical predictors for success...
  24. ncbi request reprint Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma
    Thomas W Rice
    Center for Swallowing and Esophageal Disorders and Departmentof Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, OH 44195, USA
    J Thorac Cardiovasc Surg 126:1590-6. 2003
    ..We sought to determine whether chemoradiotherapy after esophagectomy improves survival...
  25. ncbi request reprint Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy
    Ann Tan
    Taussig Cancer Center, Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    Arch Otolaryngol Head Neck Surg 133:435-40. 2007
    ....
  26. ncbi request reprint Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer
    Malcolm M Decamp
    Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Thorac Cardiovasc Surg 126:17-27. 2003
    ....
  27. ncbi request reprint Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?
    Scott A McHam
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk R 35, Cleveland, Ohio 44195, USA
    Head Neck 25:791-8. 2003
    ....
  28. doi request reprint Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck
    Cristina P Rodriguez
    Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
    Head Neck 34:1517-23. 2012
    ..This phase II study tested the addition of the oral epidermal growth factor receptor gefitinib to multiagent concurrent chemoradiotherapy regimen in head and neck squamous cell cancer (HNSCC)...
  29. doi request reprint Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohort
    Gregory M M Videtic
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Int J Radiat Oncol Biol Phys 72:702-6. 2008
    ..We used the results of mediastinoscopy from a Stage III NSCLC cohort to assess the reliability of positron emission tomography (PET) scans at identifying involved mediastinal lymph nodes (MLN) when used during radiotherapy planning...
  30. ncbi request reprint Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma
    Thomas W Rice
    Center for Swallowing and Esophageal Disorders, Departments of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Cardiovasc Surg 125:1091-102. 2003
    ..We sought to evaluate the effectiveness of clinical staging of depth of tumor invasion (cT), the relationship of cT to survival, the benefits of downstaging cT, and the role of cT in treatment decisions...
  31. ncbi request reprint Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer
    Rony M Abou-Jawde
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Taussig Cancer Center, R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Chest 128:250-5. 2005
    ..To evaluate the effects of induction concurrent chemoradiotherapy (cCRT) on pulmonary function and postoperative acute respiratory complications (PARCs)...
  32. ncbi request reprint Refining esophageal cancer staging
    Thomas W Rice
    Center for Swallowing and Esophageal Disorders, Departments of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Cardiovasc Surg 125:1103-13. 2003
    ..The objectives of this study were to assess current esophageal cancer staging and to determine whether refinements of classification and stage grouping are necessary...
  33. ncbi request reprint T2N0M0 esophageal cancer
    Thomas W Rice
    Center for Swallowing and Esophageal Disorders, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Thorac Cardiovasc Surg 133:317-24. 2007
    ..The study objective was to develop a treatment algorithm for cT2N0M0 esophageal cancer by determining (1) errors in clinical staging and (2) consequences of overtreatment and undertreatment of incorrectly clinically staged patients...
  34. doi request reprint Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly
    Stephanie A Michal
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    Head Neck 34:1147-52. 2012
    ..The reported decreasing benefit with increasing age from concurrent chemoradiotherapy in head and neck cancer patients prompted this retrospective review...
  35. ncbi request reprint Brain metastases from esophageal cancer: a phenomenon of adjuvant therapy?
    Thomas W Rice
    The Center for Swallowing and Esophageal Disorders, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Ann Thorac Surg 82:2042-9, 2049.e1-2. 2006
    ..Therefore, we determined (1) incidence and prevalence of, risk factors for, and survival after development of brain metastases following esophagectomy for esophageal cancer, and (2) their association with adjuvant therapy...
  36. doi request reprint Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification
    Gregory M M Videtic
    Department of Radiation Oncology, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 75:1141-7. 2009
    ....
  37. doi request reprint Salvage laryngectomy in patients with recurrent laryngeal cancer in the setting of nonoperative treatment failure
    Mingsi Li
    Head and Neck Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Otolaryngol Head Neck Surg 149:245-51. 2013
    ..To investigate the effectiveness of salvage partial and total laryngectomy in the treatment of recurrent laryngeal cancer in the setting of initial nonoperative treatment failure and to identify factors influencing long-term survival...
  38. ncbi request reprint Factors associated with improved survival in patients with brain metastases from esophageal cancer: a retrospective review
    Deepak Khuntia
    Brain Tumor Institute, Department of Radiation Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Technol Cancer Res Treat 2:267-72. 2003
    ..We recommend esophageal cancer patients with BrM be enrolled in clinical trials to better delineate the role of treatment and potentially improve results...
  39. ncbi request reprint Endoscopic ultrasound errors in esophageal cancer
    Gregory Zuccaro
    Department of Gastroenterology, Cleveland Clinic, Ohio, USA
    Am J Gastroenterol 100:601-6. 2005
    ..Fewer data exist on EUS errors in a cohort balanced between early and advanced disease...
  40. ncbi request reprint Stage III non-small cell lung cancer and metachronous brain metastases
    Nader Moazami
    Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Cardiovasc Surg 124:113-22. 2002
    ....
  41. doi request reprint Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review
    Shlomo A Koyfman
    Departments of Radiation and Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 84:581-9. 2012
    ....
  42. ncbi request reprint Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer-only brain metastases
    Gregory M M Videtic
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 67:240-3. 2007
    ..Clinical trials for patients with brain metastases generally exclude small-cell lung cancer (SCLC) cases. We hypothesize that the RPA classes are valid in the setting of SCLC brain metastases...
  43. ncbi request reprint P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy
    P Lavertu
    Department of Otolaryngology and Head and Neck Surgery, University Hospital of Cleveland, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Laryngoscope 111:1878-92. 2001
    ..Closer follow-up may be justified in both p53+ and Ki67+ patients to detect recurrence or a second primary at an earlier stage, possibly improving survival...
  44. doi request reprint Role of positron emission tomography in management of sinonasal neoplasms--a single institution's experience
    Eric D Lamarre
    Head and Neck Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Am J Otolaryngol 33:289-95. 2012
    ..The objective of the study is to examine the utility of positron emission tomography (PET) for staging and restaging after treatment of paranasal sinus carcinomas...
  45. ncbi request reprint Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation
    Walter T Lee
    Head and Neck Institute, Cleveland Clinic Foundation, Ohio Desk A71, 9500 Euclid Ave, Cleveland, Ohio 44195, USA
    Head Neck 28:808-12. 2006
    ..One side effect is the formation of upper esophageal strictures. As concurrent chemoradiation treatment is used more frequently, it is important to identify risk factors associated with stricture formation...
  46. doi request reprint A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer
    Balazs Halmos
    University Hospitals, Seidman Cancer Center, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH, USA
    Invest New Drugs 31:1244-50. 2013
    ....
  47. doi request reprint Intended single-modality management of T1 and T2 tonsillar carcinomas: retrospective comparison of radical tonsillectomy vs radiation from a single institution
    Eric D Lamarre
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Am J Otolaryngol 33:98-103. 2012
    ..Patients were intended to receive single-modality treatment based on presentation; however, some ultimately received adjuvant treatments...
  48. doi request reprint Current developments in the management of locally advanced esophageal cancer
    Michael J McNamara
    Cleveland Clinic Foundation, Taussig Cancer Institute, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA
    Curr Oncol Rep 14:342-9. 2012
    ..The monoclonal antibody trastuzumab appears to extend survival for patients with metastatic gastric and gastroesophageal junction adenocarcinoma and is under investigation for use in patients with loco-regionally advanced disease...
  49. ncbi request reprint Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer
    P Lavertu
    Department of Otolaryngology, Cleveland Clinic Foundation, Ohio 44195, USA
    Arch Otolaryngol Head Neck Surg 124:401-6. 1998
    ....
  50. ncbi request reprint Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer
    T W Rice
    Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA
    Ann Thorac Surg 66:1909-14. 1998
    ..This study assessed toxicity, tumor response, disease control, and survival after short-course induction chemoradiotherapy and surgical resection in patients with stage III non-small-cell lung carcinoma...
  51. ncbi request reprint N1 esophageal carcinoma: the importance of staging and downstaging
    T W Rice
    Department of Thoracic and Cardiovascular Surgery, The Center for Swallowing and Esophageal Disorders, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Cardiovasc Surg 121:454-64. 2001
    ..To evaluate the effects of clinical staging and downstaging by induction chemoradiation therapy in patients with N1 esophageal carcinoma...
  52. ncbi request reprint Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status
    T W Rice
    Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA
    Ann Thorac Surg 65:787-92. 1998
    ..A retrospective review of 359 consecutive patients undergoing esophageal resection was conducted to define the relationship between T and N and to determine whether T is a significant predictor of regional lymph node metastasis (N1)...
  53. ncbi request reprint Is there a role for folate determinations in current clinical practice in the USA?
    T Latif
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Lab Haematol 26:379-83. 2004
    ..We conclude that determination of serum folate level infrequently led to appropriate folate replacement therapy. Moreover, even when suspected, true folic acid deficiency is rare and clinical indications are not helpful in diagnosis...
  54. ncbi request reprint Superficial adenocarcinoma of the esophagus
    T W Rice
    Department of Thoracic and Cardiovascular Surgery, The Center for Swallowing and Esophageal Disorders, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Thorac Cardiovasc Surg 122:1077-90. 2001
    ..Experience with treatment and outcome of superficial adenocarcinoma of the esophagus is limited. The purpose of this study was to evaluate the results of surgical management and identify predictors of survival...
  55. pmc Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)
    Sujith R Kalmadi
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Lung Cancer 60:259-63. 2008
    ..The purpose of this open-label phase II SWOG study was to evaluate the activity of gemcitabine (Gemzar; Eli Lilly, Indiana, USA) and cisplatin combination therapy, in patients with unresectable malignant mesothelioma of the pleura...
  56. ncbi request reprint Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma
    G Mercado
    University Primary Care Practice, University Hospitals of Cleveland, Cleveland, Ohio, USA
    Cancer 92:2892-7. 2001
    ..02). CONCLUSIONS: The authors conclude that the incidence rate of hypothyroidism after patients undergo RT for head and neck carcinoma is higher than generally reported and that TSH screening after treatment appears justified...
  57. ncbi request reprint Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube?
    T M Mekhail
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer 91:1785-90. 2001
    ..Anecdotal observations of prolonged PEG dependence and of a need for pharyngoesophageal dilatation in PEG patients prompted a retrospective review of the use of both types of feeding tubes...
  58. ncbi request reprint American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer
    David G Pfister
    American Society of Clinical Oncology, Alexandria, VA, VA 22314, USA
    J Clin Oncol 24:3693-704. 2006
    ..This guideline is intended for use by oncologists in the care of patients outside of clinical trials...
  59. ncbi request reprint Induction redux: once more with taxanes
    David J Adelstein
    J Clin Oncol 23:8556-8. 2005
  60. ncbi request reprint Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial
    Susan G Urba
    University of Michigan Medical Center, Ann Arbor, USA
    J Clin Oncol 23:88-95. 2005
    ..Secondary end points were the rate of organ preservation and the need for salvage surgery...
  61. doi request reprint Redefining the role of induction chemotherapy in head and neck cancer
    David J Adelstein
    J Clin Oncol 26:3117-9. 2008